Brief: SK Bioscience Receives Approval For Global Clinical Trials Of mRNA Japanese Encephalitis Vaccine Candidate
12/12/2024 13:02
Dec 12 (Reuters) - SK Bioscience 302440.KS :
* SK BIOSCIENCE RECEIVES APPROVAL FOR GLOBAL CLINICAL TRIALS
OF
MRNA JAPANESE ENCEPHALITIS VACCINE CANDIDATE
* SK BIOSCIENCE CO LTD - CLINICAL TRIALS IN AUSTRALIA TO
START
FEBRUARY 2025, INTERIM RESULTS EXPECTED BY 2026
Source text: ID:nPn4mBmp1a
Further company coverage: 302440.KS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on SK Bioscience Co
See all newsBrief: SK Bioscience Joins Forces With Global Institutions To Advance Rotavirus Vaccine Development
Brief: SK Bioscience Files For First-In-Human Trial Of Universal Coronavirus Vaccine GBP511 Phase 1/2 Study In Australia
Novavax beats quarterly revenue estimates on milestone payment (updated)
Brief: Sk Bioscience Submits Ind For Phase 1/2 Clinical Trial Of Adjuvanted Influenza Vaccine Candidate
Brief: SK Bioscience - Wins Patent Lawsuit Against Pfizer Over Pneumococcal Vaccine